Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03476642 · ClinicalTrials.gov registry record · Phase 4
Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks
A Phase 4 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT03476642 is a Phase 4 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT03476642, a Phase 4 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objectives of this study are to define the extent of dermatomal anesthesia and anatomical spread of injectate (as defined by MRI imaging) that is provided by an ESP block at the T5 level, using twenty milliliters of 0.5% ropivacaine. The secondary objectives include: 1) the measurement of changes in hemodynamic parameters associated with the ESP block, 2) the duration of sensory effects provided by ropivacaine with or without epinephrine, 3) the venous plasma concentration of ropivacaine associated at various time intervals after completion of the ESP block.
Interventions
- DRUG Epinephrine
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03476642
The ClinicalTrials.gov registry entry for NCT03476642 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epinephrine is the first listed.
NCT03476642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03476642 about?
NCT03476642 is a clinical study titled "Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks". The primary objectives of this study are to define the extent of dermatomal anesthesia and anatomical spread of injectate (as defined by MRI imaging) that is provided by an ESP block at the T5 level, using twenty milliliters of 0.5% ropivacaine. The secondary objectives include: 1) the measurement ...
What is the current status of trial NCT03476642?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2019-07-02. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03476642?
The interventions under investigation include: Epinephrine (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT03476642?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.